What this Trial Is About

Researchers are evaluating the use of dexmedetomidine delivered through a new two-channel intravenous patient-controlled analgesia (IV-PCA) device called Bellomic4. This device allows separate infusion of drugs through two channels, one with continuous infusion plus patient-controlled bolus and the other with constant rate continuous infusion. The study focuses on patients undergoing major laparoscopic abdominal surgery, aiming to compare opioid use and pain control with and without dexmedetomidine. In this randomized controlled trial, one group receives dexmedetomidine at 0.2 mcg/kg/hr via the continuous channel of the dual-channel IV-PCA, while the control group receives normal saline at the same rate. Fentanyl is administered through the other channel in both groups with patient-controlled bolus options. This method allows researchers to study the impact of dexmedetomidine on opioid consumption and related side effects during postoperative care. Participants will be monitored for fentanyl consumption during the first 24 hours after surgery, intensity of pain, incidence of postoperative nausea and vomiting, and occurrence of postoperative delirium. The study involves tracking these outcomes alongside safety assessments to understand how dexmedetomidine influences recovery and pain management following surgery.

Two-channel IV-PCA With Dexmedetomidine